Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Condition:   Urothelial Carcinoma
Interventions:   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Durvalumab;   Drug: Nivolumab;   Drug: Avelumab
Sponsor:   Case Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 8, 2020 / by / in
Comments